Nasal immunization with mannan-decorated mucoadhesive HPMCP microspheres containing ApxIIA toxin induces protective immunity against challenge infection with Actinobacillus pleuropneumoiae in mice

Immunoprotective Efficacy of Six In vivo-Induced Antigens against Actinobacillus pleuropneumoniae as Potential Vaccine Candidates in Murine Model

“…Actinobacillus pleuropneumoniae is one of the most important bacterial pathogens, which causes PCP ( Li et al, 2016 ). For strategies aimed at controlling this disease, vaccines appear to be the most effective choice.…”

“…However, attenuated mutant vaccine candidates have been shown to provide a partial cross-protection and reduced morbidity ( Tonpitak et al, 2002 ; Maas et al, 2006 ). So far, DNA vaccines ( Chiang et al, 2009 ; Lu et al, 2011 ), subunit vaccines ( Sjolund and Wallgren, 2010 ; Lopez-Bermudez et al, 2014 ), recombinant subunit vaccines ( Jirawattanapong et al, 2008 ; Oldfield et al, 2008 , 2009 ; Shao et al, 2010 ; Sadilkova et al, 2012 ; Seo et al, 2013 ; Park et al, 2015 ; Li et al, 2016 ), ghost vaccine ( Katinger et al, 1999 ; Hensel et al, 2000 ), and live vector vaccine ( Shin et al, 2013 ; Hur and Lee, 2014 ) for APP had been studied.…”

Induction of systemic immunity through nasal-associated lymphoid tissue (NALT) of mice intranasally immunized with Brucella abortus malate dehydrogenase-loaded chitosan nanoparticles

“…To provoke mucosal immunity, an effective adjuvant and route of administration must be considered since the recombinant protein tends to be less immunogenic than the whole cell vaccine [8,9]. Among the many adjuvants, chitosan nanoparticles (CNs) which are biocompatible and nontoxic have been shown to effective delivery vesicles to induce mucosal immunity [10,11].…”

Sulfonate-modified phenylboronic acid-rich nanoparticles as a novel mucoadhesive drug delivery system for vaginal administration of protein therapeutics: improved stability, mucin-dependent release and effective intravaginal placement

“…However, insufficient interaction of the drug with mucosa and the overlaying mucus, which leads to short local placement, is the main obstacle for conventional mucosal formulations, which lead to the development of mucoadhesive drug delivery systems 2 that usually interact with mucin, which is the main component of mucus as well as mucosal membranes. 3,4 For example, as one of the most widely used mucoadhesive polymers, chitosan is believed to interact by its positively charged amino groups with the anionic counterpart in mucin (mainly sialic acid) and retain the formulation for extended time periods on the mucosa of the administration site. 5,6 Chitosan gel was reported to demonstrate high mucoadhesiveness, suitable mechanical and release properties with good vaginal retention.…”

“…For instance, modification by thiolation in drug delivery systems has been pioneered aiming to form covalent bonds with cysteine-rich subdomains of mucin. 3,10,11 Such chemical modification even further improved the mucoadhesive behavior of conventional mucoadhesive materials as demonstrated by the fivefold increase in the mucoadhesion percentage by thiolated chitosan nanoparticles than non-thiolated chitosan nanoparticles 12 and enhanced nasal bioavailability by mucoadhesive drug delivery systems based on thiolated carbopol. 13,14 As an alternative mucoadhesive strategy, phenylboronic acid (PBA) modification is attracting increasing interest for its ability to react with vicinal diol to form a stable cyclic ester 15 that makes possible effective interaction with mucin, which is rich in oligosaccharides.…”